Davis Polk Advised Mirxes On Its HK$1.09B IPO And Hong Kong listing, Supporting miRNA Diagnostics leader’s Market Expansion.
Davis Polk advised Mirxes on its HK$1.09B IPO and Hong Kong listing, supporting miRNA diagnostics leader’s market expansion.
Davis Polk advised Mirxes on its HK$1.09B IPO and Hong Kong listing, supporting miRNA diagnostics leader’s market expansion.
Davis Polk advised Mirxes Holding Company on its initial public offering and listing on the Hong Kong Stock Exchange, with gross proceeds amounting to approximately HK$1.09 billion.
Headquartered in Singapore, Mirxes is a leading micro ribonucleic acid (miRNA) technology company focused on developing accessible diagnostic solutions across key Asian markets, including Singapore and China. Its flagship product, GASTROClear, is the first and only approved molecular IVD product for gastric cancer screening globally. The offering was conducted in reliance on Regulation S.
The Davis Polk corporate team was led by partners Xuelin (Steve) Wang, Jason Xu, and James C. Lin, with counsel Wendy Kan, registered foreign lawyer Eva Xu, and associates Sarah Shi and Ching Suen. Team members are based in the firm’s Hong Kong and Beijing offices.
Click to know more about Davis Polk
If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at info@legalera.in or call us on +91 8879634922.